- Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?
Umberto Maggiore et al, 2021, Transplant International CrossRef - Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report
Ji Eun Park et al, 2022, Thoracic Cancer CrossRef - Brigatinib pharmacokinetics in patients with chronic hepatic impairment
Michael J. Hanley et al, 2023, Investigational New Drugs CrossRef - Validation of an LC-MS/MS assay for rapid and simultaneous quantification of 21 kinase inhibitors in human plasma and serum for therapeutic drug monitoring
Zaid N. Al Shirity et al, 2023, Journal of Chromatography B CrossRef - Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis
Ying Xiong et al, 2022, Frontiers in Pharmacology CrossRef - Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer
Javier Martínez‐Trufero, 2022, Cancer Medicine CrossRef - Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment
Dehua Zhao et al, 2022, Drug Design, Development and Therapy CrossRef - Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study
Abhijat Kitchlu et al, 2022, American Journal of Kidney Diseases CrossRef